Press Release by Industry
- All Industries
- Agriculture
- Automotive
- Banking
- Business Technology
- Construction
- Consumer Goods
- Consumer Technology
- Education
- Energy
- Entertainment & Media
- Environment
- Financial Services
- Food and Beverage
- General Business
- Healthcare
- Hospitality
- Information Technology
- Insurance
- Heavy Industry & Manufacturing
- Media
- Mining
- People & Culture
- Pharmaceuticals
- Policy & Public Interest
- Real Estate
- Retail
- Sports
- Telecommunications
- Transportation
- Travel
- Utilities
Healthcare - Press Releases
- 1027 Press Releases ·
- RSS
Published on Thu 20 Feb 2025 7:55:33 UTC
TAIPEI, 20. Februar 2025 /PRNewswire/ -- NaviFUS Corp. revolutioniert die Behandlung von Hirnleistungsstrungen durch ultraschallbasierte Lsungen und nutzt dabei die fortschrittliche Chiptechnologie Taiwans. Durch die Integration von IKT-Funktionen in medizinische High-End-Gerte verbessert NaviFUS die Signalverarbeitung ber die herkmmlichen medizinischen Gerte hinaus und positioniert sich als weltweit fhrendes Unternehmen fr fokussierte Ultraschallbehandlungen.
Published on Thu 20 Feb 2025 7:53:18 UTC
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-A) antibody program to Bristol Myers Squibb.Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.
Published on Thu 20 Feb 2025 7:53:17 UTC
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-A) antibody program to Bristol Myers Squibb.Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.
Published on Thu 20 Feb 2025 7:52:47 UTC
SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN
Published on Thu 20 Feb 2025 7:52:29 UTC
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli (pegcetacoplan) for the treatmentof C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.
Published on Thu 20 Feb 2025 7:51:12 UTC
SOUL, Core du Sud, 20 fvrier 2025 /PRNewswire/ -- Coway Co. Ltd, la Best Life Solution Company, a officiellement lanc son plan d'amlioration de la valeur de l'entreprise, raffirmant son engagement en faveur de l'amlioration durable de la valeur actionnariale. Aprs avoir annonc le mois dernier l'augmentation de son taux de rendement total pour l'actionnaire de 20% 40%, Coway lance prsent des initiatives stratgiques supplmentaires visant renforcer la valeur de l'entreprise.
Published on Thu 20 Feb 2025 7:51:03 UTC
SEOUL, Zuid-Korea, 20 februari 2025 /PRNewswire/ -- Coway Co., Ltd., de "Best Life Solution Company", heeft officieel zijn "Corporate Value-Up Plan" gelanceerd, waarmee het bedrijf zijn inzet voor een duurzame verbetering van de aandeelhouderswaarde opnieuw bevestigt. Na de aankondiging vorige maand om het totale aandeelhoudersrendement te verhogen van 20% naar 40%, introduceert Coway nu aanvullende strategische initiatieven gericht op het vermeerderen van de bedrijfswaarde.
Published on Thu 20 Feb 2025 7:47:54 UTC
BRUSSELS, Feb. 20, 2025 /PRNewswire/ --Mars, Incorporated - the leading pet care business - has announced the launch of the Pets and Wellbeing Study (PAWS) program. PAWS is set to become the world's largest, multi-year research program exploring the impact of cats and dogs on mental health and wellbeing, deepening our understanding of the mutual benefits of the human-animal bond.
Published on Thu 20 Feb 2025 7:45:37 UTC
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.
Published on Thu 20 Feb 2025 7:44:39 UTC
BEIJING, Feb. 20, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop" or the "Company") (NYSE: WDH), a leading technology platform specializing in insurance and healthcare services with a positive social impact, announced its strategic integration of DeepSeek, marking a significant step forward in its AI-driven insurance ecosystem. The collaboration is poised to accelerate the Company's business growth, enabling innovative breakthroughs in the application of large-scale AI models across specialized insurance scenarios.
Published on Mon 17 Feb 2025 8:08:50 UTC
NASDAQ | TSX: ACB
Published on Mon 17 Feb 2025 8:08:46 UTC
YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the latest efficacy and safety data from the phase II clinical trial (NCT05297552, Study ID: RC48-C017) of Disitamab Vedotin (DV) in combination Toripalimab as the neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC) in an oral presentation. This marks the first public disclosure of results from a prospective clinical study investigating an ADC drug in combination with an immunotherapy as a perioperative therapy for MIBC. The pathological complete response (pCR) rate reached an impressive 63.6%, which is a breakthrough improvement compared with traditional neoadjuvant chemotherapies (36%-42%). ASCO GU is one of the top urologic oncology conferences that leading experts worldwide in this field attend.
Published on Mon 17 Feb 2025 8:08:44 UTC
NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The globalgender reassignment surgery market size is estimated to grow by USD 374.2 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over11.2% during the forecast period. Increase in number of people opting for sex change surgeries globallyis driving market growth,with a trend towardsadvancements in medical technology. However,high cost of surgeries poses a challenge. Key market players include Andrew Ives., Boston Childrens Hospital, Boston Medical Center, Chettawut Plastic Surgery Center, CNY Cosmetic and Reconstructive Surgery, Crane Center, Icahn School of Medicine at Mount Sinai, IVAN MANERO CLINIC S.L., Moein Surgical Arts, Oregon Health and Science University, Phuket International Aesthetic Centre PIAC, Plastic Surgery Group of Rochester, Regents of the University of Michigan, Rumer Cosmetic Surgery, Sava Perovic Foundation Surgery, The Johns Hopkins Health System Corp., Transgender Surgery Institute, and University of Pennsylvania Health System.
Published on Mon 17 Feb 2025 8:08:39 UTC
VIRGINIA BEACH, Va., Feb. 15, 2025 /PRNewswire/ -- LifeNet Health proudly announces the launch of OraGen, the first viable dental bone allograft comprised of cryopreserved corticocancellous bone containing endogenous lineage-committedbone cells combined with demineralized bone matrix. This unique composition, the core of OraGen's innovation, delivers three essential properties for bone regeneration: osteogenicity, with lineage-committed bone cells that produce new bone; osteoconductivity, providing a biocompatible scaffold for cell attachment and growth; and osteoinduction, which stimulates bone repair through retained natural growth factors.
Published on Mon 17 Feb 2025 8:08:38 UTC
Bahnbrechende Technologie kombiniert rekombinantes menschliches Kollagen und Hyaluronsure fr sofortige, lang anhaltende Ergebnisse
Published on Mon 17 Feb 2025 8:08:33 UTC
SUN PRAIRIE, Wis., Feb. 16, 2025 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC),the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic partnership aims to enhance the capabilities and offerings for both organizations, benefiting our members and advancing independent pharmacy.
Published on Mon 17 Feb 2025 8:08:31 UTC
Revolutionising Vascular Access Care for Critically Ill Newborns and Children
Published on Mon 17 Feb 2025 8:08:30 UTC
SAN FRANCISCO and SUZHOU, China, Feb. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S.
Published on Mon 17 Feb 2025 8:07:52 UTC
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces thethird positive safety review by the independentData and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee Pharmaceuticalscontinue the trial as planned without any modification.
Published on Mon 17 Feb 2025 8:05:51 UTC
Jauna slimncas gulta paldz aprptjiem nodroint efektvu un kvalitatvu aprpi tirgos rpus ASV.
Published on Mon 17 Feb 2025 8:05:47 UTC
Uus haiglavoodi aitab hooldajatel pakkuda thusat ja kvaliteetset hooldust turgudel vljaspool USA-d
Published on Mon 17 Feb 2025 8:05:44 UTC
Nauja ligonins lova padeda slaugytojams teikti veiksming ir kokybik prieir rinkose u JAV rib.
Published on Mon 17 Feb 2025 8:05:40 UTC
OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO),The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview, bladder cancer management decisions can be made more appropriately.
Published on Mon 17 Feb 2025 8:05:39 UTC
OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO),The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview, bladder cancer management decisions can be made more appropriately.
Published on Mon 17 Feb 2025 8:05:38 UTC
RIGA, Latvia, Feb. 17, 2025 /PRNewswire/ -- The leading pharmaceutical company in theBaltics,Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time,Grindeks products will be delivered to Panama. The company's export markets already include countries such as Chile, Mexico, Australia, Singapore, the Philippines, and most of Europe. Active pharmaceutical ingredients are also exported to Japan, South Korea, and the USA.
Press Release by Industry
- All Industries
- Agriculture
- Automotive
- Banking
- Business Technology
- Construction
- Consumer Goods
- Consumer Technology
- Education
- Energy
- Entertainment & Media
- Environment
- Financial Services
- Food and Beverage
- General Business
- Healthcare
- Hospitality
- Information Technology
- Insurance
- Heavy Industry & Manufacturing
- Media
- Mining
- People & Culture
- Pharmaceuticals
- Policy & Public Interest
- Real Estate
- Retail
- Sports
- Telecommunications
- Transportation
- Travel
- Utilities